TRB Chemedica, CollPlant, Novartis, Orthocell, MiMedX group, InGeneron, R3 Stem Cell
The Tendonitis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Tendonitis pipeline products will significantly revolutionize the Tendonitis market dynamics.
DelveInsight's 'Tendonitis Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Tendonitis, historical and forecasted epidemiology as well as the Tendonitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Tendonitis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
To Know in detail about the Tendonitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Tendonitis Market Insights
Some of the key facts of the Tendonitis Market Report: The Tendonitis market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
In the 7MM, the United States held the largest market share for tendonitis, valued at approximately USD 2,500 million in 2023.
In the 7MM, the United States recorded the highest number of tendonitis incident cases, exceeding 4 million in 2023.
Key Tendonitis Companies: TRB Chemedica, CollPlant, Novartis, Orthocell, MiMedX group, InGeneron, Novartis, R3 Stem Cell, Orthocell, and others
Key Tendonitis Therapies: OSTENIL TENDON, VergenixSTR, Cosentyx (Secukinumab/AIN457), Tendon Cell Therapy, AmnioFix, Adipose-derived regenerative cells (ADRC), Secukinumab, Amniotic stem cells, Ortho-ATI, and others
Get a Free sample for the Tendonitis Market Report:
https://www.delveinsight.com/report-store/tendonitis-market
Tendonitis Overview
Tendonitis is an inflammation of a tendon – a thick, flexible cord of tissue that attaches muscles to bone and assists in moving the bone or structure. Tendonitis most commonly occurs in the shoulder, bicep, elbow, hand, wrist, thumb, calf, knee, or ankle. Since the pain of tendonitis occurs near a joint, it is sometimes mistaken for arthritis. The condition is more common in adults over the age of 40 and athletes. Some forms of tendonitis are named after certain sports (e.g., tennis elbow, golfer's elbow, pitcher's shoulder, swimmer's shoulder, and jumper's knee).
Tendonitis Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Tendonitis Epidemiology Segmentation:
The Tendonitis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Total Prevalence of Tendonitis
Prevalent Cases of Tendonitis by severity
Gender-specific Prevalence of Tendonitis
Diagnosed Cases of Episodic and Chronic Tendonitis
Download the report to understand which factors are driving Tendonitis epidemiology trends @ Tendonitis Epidemiological Insights
Tendonitis Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Tendonitis market or expected to get launched during the study period. The analysis covers Tendonitis market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Tendonitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Tendonitis Therapies and Key Companies OSTENIL TENDON: TRB Chemedica
VergenixSTR: CollPlant
Cosentyx (Secukinumab/AIN457): Novartis
Tendon Cell Therapy: Orthocell
AmnioFix: MiMedX group
Adipose-derived regenerative cells (ADRC): InGeneron
Secukinumab: Novartis
Amniotic stem cells: R3 Stem Cell
Ortho-ATI: Orthocell
Discover more about therapies set to grab major Tendonitis market share @ Tendonitis Medications
Tendonitis Market Drivers Increase in the targeted patient pool
Novel Tendonitis treatment approaches
Tendonitis Market Barriers Delayed diagnosis of the disease
Limitations associated with the current treatment
Scope of the Tendonitis Market Report Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Tendonitis Companies: TRB Chemedica, CollPlant, Novartis, Orthocell, MiMedX group, InGeneron, Novartis, R3 Stem Cell, Orthocell, and others
Key Tendonitis Therapies: OSTENIL TENDON, VergenixSTR, Cosentyx (Secukinumab/AIN457), Tendon Cell Therapy, AmnioFix, Adipose-derived regenerative cells (ADRC), Secukinumab, Amniotic stem cells, Ortho-ATI, and others
Tendonitis Therapeutic Assessment: Tendonitis current marketed and Tendonitis emerging therapies
Tendonitis Market Dynamics: Tendonitis market drivers and Tendonitis market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Tendonitis Unmet Needs, KOL's views, Analyst's views, Tendonitis Market Access and Reimbursement
To know more about Tendonitis treatment, visit @ Tendonitis Treatment Landscape
Table of Contents
1. Tendonitis Market Report Introduction
2. Executive Summary for Tendonitis
3. SWOT analysis of Tendonitis
4. Tendonitis Patient Share (%) Overview at a Glance
5. Tendonitis Market Overview at a Glance
6. Tendonitis Disease Background and Overview
7. Tendonitis Epidemiology and Patient Population
8. Country-Specific Patient Population of Tendonitis
9. Tendonitis Current Treatment and Medical Practices
10. Tendonitis Unmet Needs
11. Tendonitis Emerging Therapies
12. Tendonitis Market Outlook
13. Country-Wise Tendonitis Market Analysis (2020–2034)
14. Tendonitis Market Access and Reimbursement of Therapies
15. Tendonitis Market Drivers
16. Tendonitis Market Barriers
17. Tendonitis Appendix
18. Tendonitis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name:DelveInsight
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website:https://www.delveinsight.com/
Press Release Distributed by ABNewswire.com
To view the original version on ABNewswire visit: Tendonitis Market Growth Projections 2024-2034: DelveInsight Analysis | TRB Chemedica, CollPlant, Novartis, Orthocell, MiMedX group, InGeneron, R3 Stem Cell This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Japan Forward
11 hours ago
- Japan Forward
Can Alaska LNG Tip the Scales in Japan–US Tariff Talks?
As negotiations between Japan and the United States over President Donald Trump's tariffs intensify, a US liquefied natural gas (LNG) project is viewed as Tokyo's trump card. The project involves a 1,300-kilometer pipeline running from the North Slope gas field in northern Alaska down through the state to a newly constructed liquefaction plant. Once completed, it could supply 20 million tons of LNG annually to Japan and other East Asian countries. The concept itself has existed for a long time, but the primary obstacle has been the enormous cost. Estimated at $44 billion USD (over ¥6 trillion JPY), the project is more than twice as expensive as another LNG project currently underway in Texas. With rising material prices, the cost is expected to increase even further as the project undergoes additional review. If the project's costs are passed on to LNG prices, it could lead to "high prices" for the consumers. Scheduled to begin operations in 2030, after Trump's tenure, the project faces uncertainties. Takafumi Yanagisawa, senior researcher at The Institute of Energy Economics, Japan, points out that "the risk of policy changes following a change in administration must be carefully considered." There are clear advantages for Japan. Currently, most US-produced LNG is shipped from Gulf Coast terminals, taking roughly 30 days via the Panama Canal and about 40 days via the Cape of Good Hope. In contrast, LNG shipped from Alaska can reach Japan in under 10 days. US-produced LNG, including but not limited to that from Alaska, has another advantage: it does not contain a "destination clause" restricting resale to third parties. A tanker loaded with liquefied natural gas (LNG) arrives at a pier. (©Sankei) Japan's LNG procurement is based on long-term contracts that ensure a stable supply of a fixed volume over an extended period. But even if demand falls, such as during a warm winter, the contracted amount must still be purchased. Since US LNG contracts lack a destination clause, any surplus can be resold to other countries, helping Japan mitigate the risk of excess supply. JERA company of Japan signs Liquified Natural Gas (LNG) agreement at the U.S. Department of Energy headquarters in Washington, D.C. on June 11, 2025. (©US Department of Interior) Private companies are already expanding their procurement of US LNG. JERA, Japan's largest thermal power producer, has signed contracts with four American companies to purchase up to 5.5 million tons of LNG annually. While diversifying supply sources is the primary goal, another important factor is that "the contracts offer greater flexibility" compared to LNG imports from the Middle East, says Mineko Hida, general manager of JERA's LNG Division. JERA has also expressed interest in the Alaska LNG project. At a press conference in late June, Chairman Yukio Kani praised the concept as "very good." He emphasized the short transport time to Japan and the absence of geopolitical risks along the route, such as those linked to the Strait of Hormuz in the Middle East. JERA is reportedly closely monitoring the ongoing review of the project plan. US LNG currently accounts for about 10% of Japan's total LNG imports. With global demand for LNG expected to continue rising, increasing imports from the US will also help strengthen the country's energy security. Prime Minister Shigeru Ishiba and US President Donald Trump meet in the Oval Office, the White House, on February 7. (©Prime Minister's Office) In the Japan-US tariff negotiations, differences persist over issues such as automobile tariffs. President Trump has repeatedly labeled trade with Japan in automobiles as "unfair." However, increasing imports of American cars, which are unpopular among Japanese consumers, or reducing Japan's automobile exports, is unrealistic. If Japan concedes too easily, it risks encouraging repeated unreasonable demands. The Japanese government should therefore approach the negotiations with firmness and persistence. On the other hand, if Washington remains focused on correcting the trade imbalance, no argument about the contributions of Japanese companies to the American economy is likely to sway President Trump. The only way to break the deadlock is by expanding imports of US products that also benefit Japan. While the Alaska LNG project won't immediately reduce the US trade deficit, advancing this initiative with Japan's involvement — one of Trump's pet projects — could have a positive impact. President Donald J. Trump participates in a walking tour of Cameron LNG Export Terminal Tuesday, May 14, 2019, in Hackberry, La. (©White House/Shealah Craighead) In early June, the Ministry of Economy, Trade and Industry sent Takehiko Matsuo, the Vice Minister for International Affairs, to a US government briefing on the Alaska LNG project. While it's clear the government is considering the project as a bargaining chip, another senior Ministry official expressed caution, stating, "LNG prices are directly linked to electricity and gas rates. If the price is high, we simply won't buy it. It all depends on economic viability." So how should Japan engage with the risky Alaska LNG project? Yanagisawa stresses that if Japan decides to participate, "government involvement is essential." He suggests that development support through the Japan Oil, Gas and Metals National Corporation (JOGMEC) could be considered to help keep LNG prices affordable. Should it prove difficult for Japan to take on the project alone, another option would be to share the investment burden with other Asian LNG-importing countries and regions, such as South Korea and Taiwan. "If it's economically viable, then we should do it," the senior METI official said, without ruling out the possibility. Can we leverage the few cards we hold as negotiation tools to break the deadlock? Now is the time to apply wisdom and safeguard Japan's national interests. Author: Shunichi Takahashi, The Sankei Shimbun ( Read this in Japanese )
Cision Canada
21 hours ago
- Cision Canada
Great Northern Energy Metals Announces Exercise of First Option to Acquire Interest in Colorado Uranium Project
VANCOUVER, BC, /CNW/ - Great Northern Energy Metals Inc. (" GNEM" or the " Company") (CSE: GNEM) is pleased to announce that, further to its news releases dated May 9, 2025, June 4, 2025, and July 14, 2025, the Company has exercised the first option (the " First Option") pursuant to the terms and conditions of an Option Agreement dated August 20, 2024, entered into among 1494402 B.C. Ltd. (the " Assignor"), Ventura Uranium LLC dba Nuvemco, LLC, and Paul Szilagyi, as amended (the " Option Agreement"), as assigned to the Company pursuant to Assignment and Assumption Agreement dated May 8, 2025, entered into between the Company and the Assignor (the " Assignment Agreement"). In connection with the exercise of the First Option the Company issued 8,418,839 common shares in the capital of the Company (" Shares") and completed a cash payment of USD$750,000. Following the exercise of the First Option the Company now holds a 49% interest in NUV2C, LLC (" HoldCo") which holds title to a Colorado-based uranium project. "We are very pleased and excited to have completed the first option exercise on our Nuvemco project, this lays the foundation for our mission to become a significant player in the nuclear fuel cycle in North America"stated CEO David Mitchell. In connection with the exercise of the First Option and pursuant to the terms and conditions of the Assignment Agreement, the Company issued 2,296,969 Shares to the Assignor as reimbursement for prior expenditures totaling $758,000 which were incurred in connection with the Option Agreement. Further, the Company issued 420,942 Shares to two arm's length finders who assisted the Company with discovering the opportunity to enter into the Assignment Agreement and to acquire the membership interests in Holdco. All Shares issued in connection with the exercise of the First Option are subject to a statutory hold period of four months plus a day from the date of issuance in accordance with applicable securities legislation. This news release does not constitute an offer to sell or a solicitation of an offer to sell any of the Shares in the United States. The Shares have not been and will not be registered under the United States Securities Act of 1933, as amended (the " U.S. Securities Act"), or any state securities laws, and may not be offered or sold within the United States or to U.S. persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available. " United States" and " U.S. person" are as defined in Regulation S promulgated under the U.S. Securities Act. On Behalf of the Board of Great Northern Energy Metals Inc. "David Mitchell" CEO & Director About Great Northern Energy Metals Inc. GNEM is a Canadian-based exploration and development company focused on securing and developing critical energy metals, including uranium. The Company's mission is to support the global transition to clean energy through responsible resource development. Cautionary Note Regarding Forward-Looking Statements This news release includes certain statements that may be deemed "forward-looking statements". All statements in this new release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include market prices, continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change. Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this news release. SOURCE Great Northern Energy Metals Inc.
Cision Canada
21 hours ago
- Cision Canada
Bank of Montreal Announces AT1 Limited Recourse Capital Notes Issue Français
TORONTO, July 21, 2025 /CNW/ - Bank of Montreal (TSX: BMO) (NYSE: BMO or the "Bank") today announced the pricing of USD 1.0 billion of non-viability contingent capital ("NVCC") Additional Tier 1 (AT1) Limited Recourse Capital Notes, Series 6 (the "LRCNs"). The LRCNs will bear interest at a rate of 6.875 per cent annually, payable quarterly, for the initial period ending, but excluding, November 26, 2030. Thereafter, the interest rate on the LRCNs will reset every five years at a rate equal to the prevailing 5-year U.S. Treasury Rate plus 2.976 per cent. The LRCNs will mature on November 26, 2085. The expected closing date of the offering is July 29, 2025. On or before the issuance of the LRCNs, the Bank will issue NVCC Non-Cumulative 5-Year Fixed Rate Reset Class B Preferred Shares, Series 55 ("Preferred Shares Series 55") to be held by Computershare Trust Company of Canada, as trustee for BMO LRCN Trust (the "Limited Recourse Trust"). In the case of non-payment of interest, principal or the redemption price on the LRCNs when due or an event of default, the recourse of each LRCN holder will be limited to that holder's proportionate share of the Limited Recourse Trust's assets, which will consist of Preferred Shares Series 55 except in limited circumstances. The LRCNs may be redeemed at the option of the Bank, with the prior written approval of the Superintendent of Financial Institutions (Canada), in whole or in part, on not less than 10 nor more than 60 days' prior notice, every quarter on the interest payment date, commencing on November 26, 2030. The net proceeds will be contributed to the general funds of the Bank and will be utilized for general banking purposes, which may include the redemption of outstanding capital securities of the Bank and/or repayment of other outstanding liabilities of the Bank, and are expected to qualify as Additional Tier 1 capital of the Bank for regulatory purposes. BMO Capital Markets Corp., Citigroup Global Markets Inc., Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Barclays Capital Inc. and Mizuho Securities USA LLC are the joint book-running managers for the offering. A registration statement relating to the offering has been filed with the U.S. Securities and Exchange Commission (the "SEC") and is effective. The offering is being made only by means of a prospectus supplement and the accompanying prospectus that forms a part of the registration statement. Copies of the preliminary prospectus supplement and the accompanying prospectus for the offering may be obtained free of charge by visiting EDGAR on the SEC's website at Alternatively, copies of the final prospectus supplement, when available, and the accompanying prospectus may also be obtained by contacting BMO Capital Markets Corp. toll-free at 1-888-200-0266; Citigroup Global Markets Inc. toll-free at 1-800-831-9146; Goldman Sachs & Co. LLC toll-free at 1-866-471-2526; J.P. Morgan Securities LLC collect at 1-212-834-4533; Barclays Capital Inc. toll-free at 1-888-603-5847 and Mizuho Securities USA LLC toll-free at 1-866-271-7403. This press release does not constitute an offer to sell, or a solicitation of an offer to buy, these securities in the United States or in any other jurisdiction where such offer, solicitation or sale would be unlawful. The offering may be made only by means of a prospectus supplement and the accompanying prospectus. About BMO Financial Group BMO Financial Group is the seventh largest bank in North America by assets, with total assets of $1.4 trillion as of April 30, 2025. Serving customers for 200 years and counting, BMO is a diverse team of highly engaged employees providing a broad range of personal and commercial banking, wealth management, global markets and investment banking products and services to 13 million customers across Canada, the United States, and in select markets globally. Driven by a single purpose, to Boldly Grow the Good in business and life, BMO is committed to driving positive change in the world, and making progress for a thriving economy, sustainable future, and inclusive society. SOURCE BMO Financial Group
